Quartz 4
Search
Search
Dark mode
Light mode
Explorer
Tag: antibodies/nanobodies
17 items with this tag.
Apr 21, 2026
Most nanobodies do not bind using all three CDRs
antibodies/nanobodies
antibody-antigen-interactions/misc
Apr 21, 2026
Nanobodies and Abs target different epitopes but with similar accessibility and number of contacts
antibodies/nanobodies
antibody-antigen-interactions/misc
Apr 21, 2026
Nanobody framework residues more likely to be part of paratope than those of antibodies
antibodies/nanobodies
antibody-antigen-interactions/misc
Apr 21, 2026
Anti-nanobody immunogenic reactions disproportionately target their C-termini
antibody-developability/immunogenicity
antibodies/nanobodies
Apr 21, 2026
Kinks in nanobody CDR3 loops are correctly predicted by structure prediction methods
antibody-structure-prediction/cdr
antibodies/nanobodies
Apr 21, 2026
Most camelid-derived nanobodies have high sequence identity with human IGHV3
antibodies/nanobodies
Apr 21, 2026
Nanobodies designed de novo from sequence are more flexible than either those designed from structure or those occurring in nature
antibodies/nanobodies
Apr 21, 2026
Nanobody CDR1 and CDR2 do not conform to the canonical clustering patterns found in traditional antibodies
antibodies/nanobodies
Apr 21, 2026
Nanobody CDRH3 loops are longer but more compact
antibody-structure-prediction/cdr
antibodies/nanobodies
Apr 21, 2026
Nanobody FR2 is more hydrophilic than that of antibodies
antibody-developability/hydrophobicity
antibodies/nanobodies
Apr 21, 2026
Partial diffusion of de novo designed binders and VHHs improves refoldability and designability scores
antibody-structure-prediction/complex-prediction
antibodies/nanobodies
Apr 21, 2026
The solubilization tetrad allows camelid nanobodies to remain soluble in the absence of a light chain
antibody-developability/solubility
antibodies/nanobodies
Apr 21, 2026
CabBCII-10 is a universal nanobody framework capable of accepting diverse CDRs
antibodies/nanobodies
Apr 21, 2026
Germline usage determines whether nanobody CDR3 is kinked or extended
affinity-maturation
antibodies/nanobodies
Apr 21, 2026
Kinked nanobody CDR3s are longer than extended CDR3s
antibodies/nanobodies
Apr 21, 2026
Multiple nanobodies can bind simultaneously
antibodies/nanobodies
Apr 21, 2026
Source of immunogenicity in VHH nanobodies
antibody-developability/immunogenicity
antibodies/nanobodies